Presentation of “New Technology to Reduce Complications and Procedure Time in Cranial and Spinal Surgery” to be the first of several upcoming presentations and publications
MONTCLAIR, NJ, February 26, 2019 – Endomedix, Inc., a developer of unique biosurgical products based on natural biopolymer systems, today announced it will provide the first public presentation of its work at a scientific meeting. The 2019 Annual Meeting is scheduled for April 3-6 in Seattle, Washington. The presentation will provide data and descriptions of the performance of its patented hydrogel biomaterial in a series of hemostatic applications in progressively more challenging bleeding wounds. This data will include the information about the success rate and speed of action of the material in this application. Additionally, the presentation will provide information on the consolidation or shrinkage of its hemostatic material when placed in moist or wet environments. Currently available hemostats generally swell when placed into such environments.
“We are excited to report on the ability of our hemostat technology to not only achieve rapid consistent hemostasis, but also to support the development of stable clot formation”, noted Piyush Modak, Director of Research and Development for Endomedix. “A recent review of published reports of hemostat device performance did not locate any findings about stable clot formation or coagulation produced by these hemostats”, added Ms. Modak.
The Society For Biomaterials is a multidisciplinary society of academic, healthcare, governmental and business professionals dedicated to promoting advancements in all aspects of biomaterial science, education and professional standards to enhance human health and quality of life. In 1969, a number of researchers in the biomaterials field initiated a series of International Biomaterials Symposia concentrating predominantly on materials for reconstructive surgery. The Society For Biomaterials (SFB) was formally established in April, 1974.
About Endomedix, Inc.
Endomedix is a biological products company working with its patented platform technology to develop a series of hemostats for surgical, military and first responder uses. This platform technology will also be used to develop a set of tissue sealant, drug delivery and tissue engineering devices. Endomedix, Inc. is located at 1 Normal Avenue, Center for Environmental and Life Sciences, Suite 404, Montclair, New Jersey 07043. Website: www.Endomedix.com For more information, contact Richard Russo, CEO; e-mail – rrusso@endomedix.com or call 848 248 1883.